C-CAR011 Treatment in Subjects With ALL After HSCT
This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT
Acute Lymphoblastic Leukemia(ALL)
BIOLOGICAL: C-CAR011
TEAEs, TEAEs evaluated after C-CAR011 infusion, 2 months|GVHD, GVHD evaluated after C-CAR011 infusion, 2 months
Recurrence rate, Recurrence rate, 6 and 12 months|OS, Overall survival (OS) after C-CAR011 infusion, 12 months|PFS, Progression free survival（PFS）after C-CAR011 infusion, 12 months|Remission rate, MRD negative after C-CAR011 infusion, 2 weeks to 3 months
A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic stem cell transplantation（HSCT）. The amount of cells received：1.0-5.0×10\^6CAR+T cells/kg